Kura Oncology (KURA) reported a Q1 net loss late Tuesday of $0.83 per diluted share, widening from a loss of $0.66 a year earlier.

A single analyst polled by FactSet expected a loss of $0.83.

Total revenue for the quarter ended March 31 was $18.3 million, compared with $14.1 million a year earlier.

Analysts surveyed by FactSet expected $26 million.

Shares of Kura Oncology were down 6% in after-hours trading.